Haemoglobin targets: we were wrong, time to move on

Lancet

Volumn 369, Issue 9559, 2007, Pages 346-350

  Strippoli, Giovanni FM ^a,b   Tognoni, Giovanni ^b   Navaneethan, Sankar D ^c   Nicolucci, Antonio ^b   Craig, Jonathan C ^a  

^a University of Sydney   (Australia)

^b Consorzio Mario Negri Sud ^*  (Italy)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; THROMBOSIS;

EID: 33846677380     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60165-2     Document Type: Note

References (18)

1. US Renal Data System. Annual data report, 2006: Atlas of end-stage renal disease in the United States. http://www.usrds.org/adr.htm (accessed Jan 23, 2007)
2. Locatelli F., Pisoni R., Combe C., et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 121-132
3. Stevens L., Stigant C., and Levin A. Should hemoglobin be normalized in patients with chronic kidney disease?. Semin Dial 15 (2002) 8-13
4. Strippoli G., Navaneethan S., and Craig J. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 4 (2006) CD003967
5. Phrommintikul A., Haas S., Elsik M., and Klum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369 (2007) 381-388
6. Singh A., Szczech L., Tang K., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
7. Drueke T., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
8. Besarab A., Bolton W., Browne J., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
9. Remuzzi G., and Ingelfinger J. Correction of anemia-payoffs and problems. N Engl J Med 355 (2006) 2144-2146
10. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet 368 (2006) 2191-2193
11. Locatelli F., Del Vechhio L., and Pozzoni P. Anemia and cardiovascular risk: the lesson of the CREATE trial. J Am Soc Nephrol 17 (2006) S262-S266
12. Volkova N., and Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 47 (2006) 24-36
13. Armstrong D. Medical journal spikes article on industry ties of kidney group. Wall Street J. http://online.wsj.com/article/SB116709354076459273.html (accessed Jan 24, 2007)
14. The Lancet Oncology. Epoetin: for better or for worse?. Lancet Oncol 5 (2004) 1
15. Ioannidis J., and Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials. A proposed evaluation algorithm. Am J Epidemiol 148 (1998) 1117-1126
16. Mix T., Brenner R., Cooper M., et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149 (2005) 408-413
17. Strippoli G., Craig J., Manno C., and Schena F. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15 (2004) 3154-3165
18. Strippoli G., and Craig J. Hypothesis versus association: the optimal hemoglobin target debate. Am J Kidney Dis 46 (2005) 970-973